Boehringer Ingelheim International Gmbh

Markus Frank

Waldemar F Pfrengle

Marco Santagostino

Thomas Klein

Thorsten Pachur

Uwe Stertz

Ulrike Werthmann

Juergen Schnaubelt

Manuel Henry

Hans Haeberle

Thomas Trebing

Matthias Eckhardt

Georg Dahmann

Holger Wagner

Tobias Wunberg

Anke Baum

Juergen Ramharter

Heinz Stadtmueller

Markus Ostermeier

Adil Duran

Christiane Kofink

Dorothea Ingrid Rudolph

Annika Gille

Stefan Goepper

Marco Hans Hofmann

Michael Gmachl

Julian Wippich

Fabio Savarese

Günther Huchler

The present invention encompasses compounds of formula (1) wherein the groups Rto R, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors

This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Co-crystals and salts of CCR3-inhibitors

The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions

The present invention relates to compounds of formula I wherein Rdenotes F or CF, Rdenotes H or C-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.

Process and intermediates for preparing GPR40 agonists

The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV(DPP-IV).

The present invention relates to substituted quinazolines of formula (I): wherein X and Y are defined as in claim, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

The present invention relates to a method of preparing compounds of general formula I wherein m, n, Rand Rare defined as mentioned hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases.

Process for making certain compounds having B1 antagonistic activity

Growing community of inventors

Ulm, Germany

Markus Frank